These Chinese Biotechs Are Severely Undervalued
Those who remember the bursting of the tech bubble at the turn of the millennium may have the nagging feeling that something vaguely similar, though on a smaller scale, just happened with biotech.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 2396 Top Specialty Pharmaceutical Stocks to Buy With Over 100% Upside Potential
24/7 Wall St. screened the RBC specialty pharmaceutical universe and found six companies rated Outperform with over 100% upside to the firm's price target.
Amgen Beats Earnings With Solid Outlook For 2015
ThinkstockAmgen Inc. (NASDAQ: AMGN) released its third quarter earnings report Wednesday after the markets closed. The biotech giant had $2.72 in earnings per share (EPS) on $5.72 billion in revenue compared to consensus estimates…
What to Expect From Amgen Earnings
Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.
With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains
With specialty pharmaceutical stocks having the chance to move dramatically higher, three large cap leaders are RBC's favorites now.
Boston Scientific Posts Solid Earnings Beat
Boston Scientific reported better-than-expected third-quarter financial results before the markets opened on Wednesday.
Are Gilead Earnings Enough for Investors?
Gilead Sciences reported its third-quarter financial results after the markets closed on Tuesday.
What to Look For in Gilead Earnings
Gilead Sciences is set to report its third-quarter financial results after the markets close on Thursday.
After HCA Earnings, Should Hospitals Use Cash for Stock Buybacks?
HCA is out with earnings, but there is a serious question here when it comes to the greater good: should it, or other hospitals, be buying back stock?
How Pfizer Stacks Up Against Merck on Earnings
Pfizer and Merck both released their third-quarter earnings on Tuesday morning. So, which drug giant is looking better after earnings?
Short Sellers Have Mixed Views on Major Pharma
The October 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was mixed.
Short Sellers Become More Selective on Leading Biotechs
The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
What to Look For in Pfizer’s Earnings
Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
What to Expect From Merck Earnings
Merckis expected to report its third-quarter financial results before the markets open on Tuesday.
How an FDA Approval Changes the Game for Endo and BioDelivery Sciences
Endo International and BioDelivery Sciences have announced that the U.S. Food and Drug Administration (FDA) approved their long-term opioid treatment, Belbuca.